Trending Tickers: $ASTS Japan Satellite Venture, $NRG $4 Billion Asset Sale, $MIRM Phase 3 Trial Result

This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:

AST SpaceMobile ($ASTS): A Satellite Network Venture in Japan

AST SpaceMobile and Rakuten announced plans to establish Rakuten AST, a joint venture intended to build a satellite network that connects directly to ordinary smartphones in Japan. Rakuten will hold 51% of the venture’s voting rights and an AST subsidiary 49%. AST is expected to supply the satellites, while the venture will procure and operate the network.

The project is expected to receive up to 148 billion yen, or approximately $1 billion, in Japanese government support over roughly three years. That is funding for the project, not revenue awarded directly to AST. The network is intended to extend coverage to underserved areas and keep phones connected during disasters. Domestic operations are targeted to begin by the end of March 2029.

For AST, the venture could create demand for its satellite hardware and give it a role in a national communications network. The questions now are how much of the project becomes contracted revenue for AST, when satellites can be delivered, and whether the partners can meet the deployment timetable.

Stock Price Reaction

$ASTS closed at $36.89 on Monday, November 9, up 14.1% after the joint venture announcement. The company released quarterly results after the market closed, so the regular-session gain preceded those results.

NRG Energy ($NRG): Selling Power Plants for $4 Billion

NRG Energy agreed to sell six natural-gas power plants to LS Power for $4 billion in cash, subject to closing adjustments. Together, the plants represent about 4.9 gigawatts of generation capacity. NRG sells electricity and natural gas to customers, so the transaction changes both the assets it owns and the cash available for other uses.

NRG said the sale will support a plan for $3 billion in share repurchases across 2026 and 2027. After the transaction closes, it also plans an additional $2 billion of debt reduction. NRG expects to retain about 20 gigawatts of generation capacity nationwide following the sale. For investors, the deal puts a cash price on part of its power-plant portfolio while giving management room to reduce debt and buy back shares.

The sale is targeted to close in the second quarter of 2027 and still requires regulatory approvals. Its value to shareholders will depend in part on the final proceeds and how NRG deploys them. The announced repurchases and debt reduction are plans, rather than transactions already completed.

Stock Price Reaction

$NRG closed at $97.40 on Monday, November 9, up 10.3%. NRG also reported quarterly results that morning, so the full stock move cannot be attributed to the asset sale alone.

Mirum Pharmaceuticals ($MIRM): A Second Phase 3 Success

Mirum Pharmaceuticals reported that brelovitug met the primary endpoint in its Phase 3 AZURE-4 study for chronic hepatitis delta, a serious liver infection that occurs in people with hepatitis B. Brelovitug is an investigational treatment; this was a clinical trial result, not a drug approval.

The study enrolled 113 patients. At week 24, 59% of those assigned to the once-weekly dose and 44% assigned to the once-every-four-weeks dose met the combined measure of viral response and normalization of a liver enzyme called ALT. No patients in the delayed-treatment comparison group met that measure. Mirum said it observed no new safety signals, although the full results remain to be presented.

AZURE-4 is the second Phase 3 study Mirum expects to use in its U.S. application; the company announced a positive result from AZURE-1 in September. Mirum plans to submit a biologics license application in the first half of 2027. The next steps are the full data presentation, the FDA filing, and regulatory review. Any U.S. launch depends on approval.

Stock Price Reaction

$MIRM closed at $94.42 on Tuesday, November 10, up 1.3%. The restrained move contrasts with the large one-day gains in the other two stocks; Mirum had already disclosed a positive result from the first Phase 3 study.

This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.